title: Clinical trials of biosimilars should become more similar.
authors: Division of Rheumatology, Department of Medicine, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, Massachusetts, USA.
authors: Jonathan
authors: 0000-0002-8970-4260
authors: J
authors: Kay
authors: Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and National Institute of Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne, UK.
authors: John D
authors: JD
authors: Isaacs
mesh_terms: D018501:Antirheumatic Agents; D001172:Arthritis, Rheumatoid; D059451:Biosimilar Pharmaceuticals; D000069285:Infliximab; D014409:Tumor Necrosis Factor-alpha
chemical_list: D018501:Antirheumatic Agents; D059451:Biosimilar Pharmaceuticals; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab
keywords: Anti-TNF; Disease Activity; Inflammation; Rheumatoid Arthritis; Treatment